

Leonidas C Plataniias

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7056599/leonidas-c-plataniias-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

227
papers

17,952
citations

60
h-index

131
g-index

239
ext. papers

19,944
ext. citations

5.4
avg, IF

6.71
L-index

#	Paper	IF	Citations
227	Abstract P2-02-05: Dynamic circulating tumor cell changes in enumeration and HER2 expression during systemic therapy for metastatic breast cancer. <i>Cancer Research</i> , 2022 , 82, P2-02-05-P2-02-05	10.1	
226	Abstract PD14-01: Comprehensive molecular characterization of patients with metastatic invasive lobular carcinoma (ILC): Using real-world data to describe this unique clinical entity. <i>Cancer Research</i> , 2022 , 82, PD14-01-PD14-01	10.1	
225	Abstract P2-01-04: Esr1 hotspot mutations in circulating tumor DNA mutation are associated with endocrine therapy resistance in metastatic breast cancer. <i>Cancer Research</i> , 2022 , 82, P2-01-04-P2-01-04	10.1	
224	Abstract P2-01-08: Esr1 Y537 mutations are associated with increased baseline circulating tumor cells enumeration for patients with estrogen receptor positive metastatic breast cancer. <i>Cancer Research</i> , 2022 , 82, P2-01-08-P2-01-08	10.1	
223	Abstract P1-02-11: Somatic alterations and PD-L1 positivity in advanced breast cancer. <i>Cancer Research</i> , 2022 , 82, P1-02-11-P1-02-11	10.1	0
222	Discovery of a signaling feedback circuit that defines interferon responses in myeloproliferative neoplasms.. <i>Nature Communications</i> , 2022 , 13, 1750	17.4	0
221	Cell-directed aptamer therapeutic targeting for cancers including those within the central nervous system.. <i>Onc Immunology</i> , 2022 , 11, 2062827	7.2	0
220	Regulation of IFN-induced expression of the short ACE2 isoform by ULK1.. <i>Molecular Immunology</i> , 2022 , 147, 1-9	4.3	
219	The Use of Serial Circulating Tumor DNA to Detect Resistance Alterations in Progressive Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 1361-1370	12.9	5
218	Type I and II Interferons in the Anti-Tumor Immune Response. <i>Cancers</i> , 2021 , 13,	6.6	11
217	Schlafen 5 as a novel therapeutic target in pancreatic ductal adenocarcinoma. <i>Oncogene</i> , 2021 , 40, 3273-3286	3.286	1
216	Inhibitory effects of Tomivosertib in acute myeloid leukemia. <i>Oncotarget</i> , 2021 , 12, 955-966	3.3	1
215	Longitudinal Dynamics of Circulating Tumor Cells and Circulating Tumor DNA for Treatment Monitoring in Metastatic Breast Cancer. <i>JCO Precision Oncology</i> , 2021 , 5, 943-952	3.6	1
214	Understanding the organ tropism of metastatic breast cancer through the combination of liquid biopsy tools. <i>European Journal of Cancer</i> , 2021 , 143, 147-157	7.5	11
213	Interferon maintenance for prevention of relapse in favorable risk AML?. <i>Leukemia and Lymphoma</i> , 2021 , 62, 2818-2819	1.9	
212	Glioblastoma as an age-related neurological disorder in adults. <i>Neuro-Oncology Advances</i> , 2021 , 3, vdab125	12.5	5
211	Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma. <i>Clinical Cancer Research</i> , 2020 , 26, 5232-5245	12.9	27

210	Hematological manifestations of COVID-19. <i>Leukemia and Lymphoma</i> , 2020 , 61, 2790-2798	1.9	15
209	An aberrantly sustained emergency granulopoiesis response accelerates postchemotherapy relapse in -rearranged acute myeloid leukemia in mice. <i>Journal of Biological Chemistry</i> , 2020 , 295, 9663-9675	5.4	0
208	Combined PI3K/mTOR Targeting of Glioma Stem Cells. <i>Scientific Reports</i> , 2020 , 10, 21873	4.9	7
207	Performance of a novel Next Generation Sequencing circulating tumor DNA (ctDNA) platform for the evaluation of samples from patients with metastatic breast cancer (MBC). <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 145, 102856	7	12
206	Type I Interferon (IFN)-Regulated Activation of Canonical and Non-Canonical Signaling Pathways. <i>Frontiers in Immunology</i> , 2020 , 11, 606456	8.4	22
205	Landscape of circulating tumour DNA in metastatic breast cancer. <i>EBioMedicine</i> , 2020 , 58, 102914	8.8	19
204	Pharmacological mTOR targeting enhances the antineoplastic effects of selective PI3K inhibition in medulloblastoma. <i>Scientific Reports</i> , 2019 , 9, 12822	4.9	11
203	Myeloid-Derived Suppressive Cells Promote B cell-Mediated Immunosuppression via Transfer of PD-L1 in Glioblastoma. <i>Cancer Immunology Research</i> , 2019 , 7, 1928-1943	12.5	44
202	Natural killer cell activity and survival after azacitidine treatment in high-risk MDS. <i>Leukemia and Lymphoma</i> , 2019 , 60, 2343-2344	1.9	
201	Potent Antineoplastic Effects of Combined PI3K/mTOR Inhibition in Medulloblastoma. <i>Molecular Cancer Research</i> , 2019 , 17, 1305-1315	6.6	8
200	Impact of myosteatorsis in survivors of childhood acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2019 , 60, 3097-3098	1.9	1
199	Discovery of novel Mnk inhibitors using mutation-based induced-fit virtual high-throughput screening. <i>Chemical Biology and Drug Design</i> , 2019 , 94, 1813-1823	2.9	4
198	Inhibitory effects of SEL201 in acute myeloid leukemia. <i>Oncotarget</i> , 2019 , 10, 7112-7121	3.3	5
197	Interferon signaling in cancer. Non-canonical pathways and control of intracellular immune checkpoints. <i>Seminars in Immunology</i> , 2019 , 43, 101299	10.7	13
196	Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer. <i>Breast Cancer Research</i> , 2019 , 21, 137	8.3	25
195	Identification and targeting of novel CDK9 complexes in acute myeloid leukemia. <i>Blood</i> , 2019 , 133, 1171-1185	11.85	17
194	Sirtuin 2-mediated deacetylation of cyclin-dependent kinase 9 promotes STAT1 signaling in type I interferon responses. <i>Journal of Biological Chemistry</i> , 2019 , 294, 827-837	5.4	19
193	The E3 ubiquitin ligase Triad1 influences development of Mll-Ell-induced acute myeloid leukemia. <i>Oncogene</i> , 2018 , 37, 2532-2544	9.2	8

192	IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma. <i>Clinical Cancer Research</i> , 2018 , 24, 2559-2573	12.9	95
191	HDL nanoparticles targeting sonic hedgehog subtype medulloblastoma. <i>Scientific Reports</i> , 2018 , 8, 12114-9	4.9	23
190	Transforming growth factor superfamily ligands and links to tumorigenesis. <i>Leukemia and Lymphoma</i> , 2018 , 59, 1282-1283	1.9	1
189	Implications of high EVI1 expression in high-risk myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2018 , 59, 2765-2766	1.9	
188	Rapamycin Modulates Glucocorticoid Receptor Function, Blocks Atrophogene REDD1, and Protects Skin from Steroid Atrophy. <i>Journal of Investigative Dermatology</i> , 2018 , 138, 1935-1944	4.3	19
187	Differential Response of Glioma Stem Cells to Arsenic Trioxide Therapy Is Regulated by MNK1 and mRNA Translation. <i>Molecular Cancer Research</i> , 2018 , 16, 32-46	6.6	25
186	SIfn2 Regulates Type I Interferon Responses by Modulating the NF- κ B Pathway. <i>Molecular and Cellular Biology</i> , 2018 , 38,	4.8	6
185	Circulating tumor cells enumeration (CTCs) and circulating tumor DNA (ctDNA): Clinical and molecular features of rapidly progressing stage IV disease (Stage IVprog).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 12040-12040	2.2	
184	IFN- γ -inducible antiviral responses require ULK1-mediated activation of MLK3 and ERK5. <i>Science Signaling</i> , 2018 , 11,	8.8	7
183	Spontaneous remission in congenital leukemia. <i>Leukemia and Lymphoma</i> , 2018 , 59, 2271-2272	1.9	2
182	Dual targeting of eIF4E by blocking MNK and mTOR pathways in leukemia. <i>Cytokine</i> , 2017 , 89, 116-121	4	16
181	Another tyrosine kinase inhibitor-resistance mutation within the BCR-ABL kinase domain: chasing our tails?. <i>Leukemia and Lymphoma</i> , 2017 , 58, 1526-1527	1.9	1
180	Central Regulatory Role for SIN1 in Interferon γ (IFN γ) Signaling and Generation of Biological Responses. <i>Journal of Biological Chemistry</i> , 2017 , 292, 4743-4752	5.4	5
179	Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2017 , 16, 1412-1420	6.1	77
178	PD1 and PDL1 upregulation and survival after decitabine treatment in lower risk MDS. <i>Leukemia and Lymphoma</i> , 2017 , 58, 764-765	1.9	3
177	Discovery and characterization of novel small-molecule CXCR4 receptor agonists and antagonists. <i>Scientific Reports</i> , 2016 , 6, 30155	4.9	37
176	Targeting the mTOR Pathway in Leukemia. <i>Journal of Cellular Biochemistry</i> , 2016 , 117, 1745-52	4.7	40
175	Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia. <i>Cancer Research</i> , 2016 , 76, 4841-4849	10.1	26

174	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016 , 12, 1-222	10.2	3838
173	Differential Regulation of ZEB1 and EMT by MAPK-Interacting Protein Kinases (MNK) and eIF4E in Pancreatic Cancer. <i>Molecular Cancer Research</i> , 2016 , 14, 216-27	6.6	29
172	Evolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative Neoplasms. <i>EBioMedicine</i> , 2016 , 3, 17-25	8.8	4
171	Interferon γ Signaling via Mechanistic Target of Rapamycin Complex 2 (mTORC2) and Regulatory Effects in the Generation of Type II Interferon Biological Responses. <i>Journal of Biological Chemistry</i> , 2016 , 291, 2389-96	5.4	19
170	Whole-exome sequencing for relapse prediction in patients discontinuing TKI treatment in chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2016 , 57, 1503-4	1.9	1
169	The Interferon Consensus Sequence Binding Protein (Icsbp/Irf8) Is Required for Termination of Emergency Granulopoiesis. <i>Journal of Biological Chemistry</i> , 2016 , 291, 4107-20	5.4	12
168	Targeting of glioblastoma cell lines and glioma stem cells by combined PIM kinase and PI3K-p110 α inhibition. <i>Oncotarget</i> , 2016 , 7, 33192-201	3.3	18
167	Mesenchymal stromal cells and Interferon γ in cancer immunotherapy. <i>Translational Cancer Research</i> , 2016 , 5, S1039-S1043	0.3	1
166	Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA. <i>Oncotarget</i> , 2016 , 7, 65364-65373	3.3	69
165	A simple, low-cost staining method for rapid-throughput analysis of tumor spheroids. <i>BioTechniques</i> , 2016 , 60, 43-6	2.5	10
164	MNK Inhibition Disrupts Mesenchymal Glioma Stem Cells and Prolongs Survival in a Mouse Model of Glioblastoma. <i>Molecular Cancer Research</i> , 2016 , 14, 984-993	6.6	25
163	Beyond autophagy: New roles for ULK1 in immune signaling and interferon responses. <i>Cytokine and Growth Factor Reviews</i> , 2016 , 29, 17-22	17.9	13
162	SNPing away to individualize induction therapy for acute myelogenous leukemia. <i>Leukemia and Lymphoma</i> , 2016 , 57, 742-3	1.9	
161	Merestinib blocks Mnk kinase activity in acute myeloid leukemia progenitors and exhibits antileukemic effects in vitro and in vivo. <i>Blood</i> , 2016 , 128, 410-4	2.2	28
160	Overcoming treatment challenges in imatinib-resistant chronic myelogenous leukemia. <i>Leukemia and Lymphoma</i> , 2015 , 56, 1581-2	1.9	
159	IRF8 directs stress-induced autophagy in macrophages and promotes clearance of Listeria monocytogenes. <i>Nature Communications</i> , 2015 , 6, 6379	17.4	44
158	Targeting mTOR signaling pathways and related negative feedback loops for the treatment of acute myeloid leukemia. <i>Cancer Biology and Therapy</i> , 2015 , 16, 648-56	4.6	28
157	Rituximab and glucocorticoids: friends or foes? It is all about timing. <i>Leukemia and Lymphoma</i> , 2015 , 56, 2237-8	1.9	

156	Catalytic mammalian target of rapamycin inhibitors as antineoplastic agents. <i>Leukemia and Lymphoma</i> , 2015 , 56, 2518-23	1.9	
155	Synergism between arsenic trioxide and aclacinomycin in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2015 , 56, 3010-1	1.9	
154	Intersection of mTOR and STAT signaling in immunity. <i>Trends in Immunology</i> , 2015 , 36, 21-9	14.4	86
153	Human Schlafen 5 (SLFN5) Is a Regulator of Motility and Invasiveness of Renal Cell Carcinoma Cells. <i>Molecular and Cellular Biology</i> , 2015 , 35, 2684-98	4.8	31
152	Direct binding of arsenic trioxide to AMPK and generation of inhibitory effects on acute myeloid leukemia precursors. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 202-12	6.1	21
151	Central role of ULK1 in type I interferon signaling. <i>Cell Reports</i> , 2015 , 11, 605-17	10.6	45
150	Pre-clinical evidence of PIM kinase inhibitor activity in BCR-ABL1 unmutated and mutated Philadelphia chromosome-positive (Ph+) leukemias. <i>Oncotarget</i> , 2015 , 6, 33206-16	3.3	10
149	The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression. <i>Oncotarget</i> , 2015 , 6, 37930-47	3.3	26
148	Autophagy is a survival mechanism of acute myelogenous leukemia precursors during dual mTORC2/mTORC1 targeting. <i>Clinical Cancer Research</i> , 2014 , 20, 2400-9	12.9	74
147	Interferon receptor signaling in malignancy: a network of cellular pathways defining biological outcomes. <i>Molecular Cancer Research</i> , 2014 , 12, 1691-703	6.6	61
146	Regulation of interferon-dependent mRNA translation of target genes. <i>Journal of Interferon and Cytokine Research</i> , 2014 , 34, 289-96	3.5	21
145	Resveratrol enhances the suppressive effects of arsenic trioxide on primitive leukemic progenitors. <i>Cancer Biology and Therapy</i> , 2014 , 15, 473-8	4.6	11
144	Critical roles for Rictor/Sin1 complexes in interferon-dependent gene transcription and generation of antiproliferative responses. <i>Journal of Biological Chemistry</i> , 2014 , 289, 6581-6591	5.4	17
143	Pediatric acute lymphoblastic leukemia: the missing pieces in risk and survival. <i>Leukemia and Lymphoma</i> , 2014 , 55, 2226-7	1.9	1
142	Use of mTOR inhibitors in the treatment of malignancies. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 979-90	4	4
141	Regulatory effects of SKAR in interferon β signaling and its role in the generation of type I IFN responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 11377-82	11.5	6
140	New insights into malignant cell survival mechanisms in medulloblastoma. <i>Cancer Cell & Microenvironment</i> , 2014 , 1,		2
139	Regulatory effects of a Mnk2-eIF4E feedback loop during mTORC1 targeting of human medulloblastoma cells. <i>Oncotarget</i> , 2014 , 5, 8442-51	3.3	32

138	Mnk kinase pathway: Cellular functions and biological outcomes. <i>World Journal of Biological Chemistry</i> , 2014 , 5, 321-33	3.8	95
137	STAT activation in malignancies: roles in tumor progression and in the generation of antineoplastic effects of IFNs. <i>Journal of Interferon and Cytokine Research</i> , 2013 , 33, 181-8	3.5	7
136	Tyrosine kinase inhibition in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2013 , 54, 1351-2	1.9	
135	Antileukemic properties of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. <i>Leukemia and Lymphoma</i> , 2013 , 54, 2601-5	1.9	12
134	Interferons and their antitumor properties. <i>Journal of Interferon and Cytokine Research</i> , 2013 , 33, 143-4	3.5	19
133	The schlafen family of proteins and their regulation by interferons. <i>Journal of Interferon and Cytokine Research</i> , 2013 , 33, 206-10	3.5	85
132	Next generation of mammalian target of rapamycin inhibitors for the treatment of cancer. <i>Expert Opinion on Investigational Drugs</i> , 2013 , 22, 715-22	5.9	15
131	Acute myeloid leukemia: potential for new therapeutic approaches targeting mRNA translation pathways. <i>International Journal of Hematologic Oncology</i> , 2013 , 2,	1	5
130	Expression and regulatory effects of murine Schlafen (Slfn) genes in malignant melanoma and renal cell carcinoma. <i>Journal of Biological Chemistry</i> , 2013 , 288, 33006-15	5.4	24
129	Essential role for the Mnk pathway in the inhibitory effects of type I interferons on myeloproliferative neoplasm (MPN) precursors. <i>Journal of Biological Chemistry</i> , 2013 , 288, 23814-22	5.4	16
128	BCR-ABL1-induced leukemogenesis and autophagic targeting by arsenic trioxide. <i>Autophagy</i> , 2013 , 9, 93-4	10.2	12
127	Regulation of the kinase RSK1 by arsenic trioxide and generation of antileukemic responses. <i>Cancer Biology and Therapy</i> , 2013 , 14, 411-6	4.6	7
126	Inhibition of Mnk kinase activity by cercosporamide and suppressive effects on acute myeloid leukemia precursors. <i>Blood</i> , 2013 , 121, 3675-81	2.2	73
125	Regulatory effects of sestrin 3 (SESN3) in BCR-ABL expressing cells. <i>PLoS ONE</i> , 2013 , 8, e78780	3.7	8
124	Targeting AMPK in the treatment of malignancies. <i>Journal of Cellular Biochemistry</i> , 2012 , 113, 404-9	4.7	33
123	Statin-dependent activation of protein kinase C δ in acute promyelocytic leukemia cells and induction of leukemic cell differentiation. <i>Leukemia and Lymphoma</i> , 2012 , 53, 1779-84	1.9	12
122	An overview of the mTOR pathway as a target in cancer therapy. <i>Expert Opinion on Therapeutic Targets</i> , 2012 , 16, 481-9	6.4	28
121	Autophagic degradation of the BCR-ABL oncoprotein and generation of antileukemic responses by arsenic trioxide. <i>Blood</i> , 2012 , 120, 3555-62	2.2	98

120	Guidelines for the use and interpretation of assays for monitoring autophagy. <i>Autophagy</i> , 2012 , 8, 445-544.2	4.2	2783
119	Sprouty proteins are negative regulators of interferon (IFN) signaling and IFN-inducible biological responses. <i>Journal of Biological Chemistry</i> , 2012 , 287, 42352-60	5.4	30
118	Mnk Kinases in Cytokine Signaling and Regulation of Cytokine Responses. <i>Biomolecular Concepts</i> , 2012 , 3, 127-139	3.7	28
117	Regulatory effects of mTORC2 complexes in type I IFN signaling and in the generation of IFN responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 7723-8	11.5	41
116	Regulatory effects of programmed cell death 4 (PDCD4) protein in interferon (IFN)-stimulated gene expression and generation of type I IFN responses. <i>Molecular and Cellular Biology</i> , 2012 , 32, 2809-22	4.8	22
115	Regulation of mammalian target of rapamycin and mitogen activated protein kinase pathways by BCR-ABL. <i>Leukemia and Lymphoma</i> , 2011 , 52 Suppl 1, 45-53	1.9	27
114	Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignancies. <i>Current Opinion in Oncology</i> , 2011 , 23, 578-86	4.2	39
113	Antileukemic effects of AMPK activators on BCR-ABL-expressing cells. <i>Blood</i> , 2011 , 118, 6399-402	2.2	60
112	Antiviral effects of interferon- λ are enhanced in the absence of the translational suppressor 4E-BP1 in myocarditis induced by Coxsackievirus B3. <i>Antiviral Therapy</i> , 2011 , 16, 577-84	1.6	12
111	Mechanisms of BCR-ABL leukemogenesis and novel targets for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2011 , 52 Suppl 1, 2-3	1.9	2
110	Essential role for Mnk kinases in type II interferon (IFN γ) signaling and its suppressive effects on normal hematopoiesis. <i>Journal of Biological Chemistry</i> , 2011 , 286, 6017-26	5.4	26
109	Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors. <i>Clinical Cancer Research</i> , 2011 , 17, 4378-88	12.9	86
108	Protein kinase R as mediator of the effects of interferon (IFN) gamma and tumor necrosis factor (TNF) alpha on normal and dysplastic hematopoiesis. <i>Journal of Biological Chemistry</i> , 2011 , 286, 27506-14	5.4	20
107	Regulatory effects of ribosomal S6 kinase 1 (RSK1) in IFN signaling. <i>Journal of Biological Chemistry</i> , 2011 , 286, 1147-56	5.4	17
106	Targeting mTOR for the treatment of AML. New agents and new directions. <i>Oncotarget</i> , 2011 , 2, 510-7	3.3	80
105	AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications. <i>Oncotarget</i> , 2011 , 2, 1322-8	3.3	39
104	Arsenic trioxide-dependent activation of thousand-and-one amino acid kinase 2 and transforming growth factor-beta-activated kinase 1. <i>Molecular Pharmacology</i> , 2010 , 77, 828-35	4.3	8
103	Role of interferon {alpha} (IFN{alpha})-inducible Schlafen-5 in regulation of anchorage-independent growth and invasion of malignant melanoma cells. <i>Journal of Biological Chemistry</i> , 2010 , 285, 40333-41	5.4	57

102	Autophagy is a critical mechanism for the induction of the antileukemic effects of arsenic trioxide. <i>Journal of Biological Chemistry</i> , 2010 , 285, 29989-97	5.4	98
101	Arsenic trioxide and the phosphoinositide 3-kinase/akt pathway in chronic lymphocytic leukemia. <i>Clinical Cancer Research</i> , 2010 , 16, 4311-2	12.9	19
100	Negative regulatory effects of Mnk kinases in the generation of chemotherapy-induced antileukemic responses. <i>Molecular Pharmacology</i> , 2010 , 78, 778-84	4.3	33
99	Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 12469-74	11.5	157
98	Induction of autophagy by dual mTORC1-mTORC2 inhibition in BCR-ABL-expressing leukemic cells. <i>Autophagy</i> , 2010 , 6, 966-967	10.2	19
97	AMPK as a therapeutic target in renal cell carcinoma. <i>Cancer Biology and Therapy</i> , 2010 , 10, 1168-77	4.6	49
96	Deregulation of Interferon Signaling in Malignant Cells. <i>Pharmaceuticals</i> , 2010 , 3, 406-418	5.2	21
95	Mechanisms of mRNA translation of interferon stimulated genes. <i>Cytokine</i> , 2010 , 52, 123-7	4	39
94	AMP-activated kinase (AMPK)-generated signals in malignant melanoma cell growth and survival. <i>Biochemical and Biophysical Research Communications</i> , 2010 , 398, 135-9	3.4	49
93	Abnormalities in Th17 T cells in aplastic anemia. <i>Blood</i> , 2010 , 116, 4039-40	2.2	5
92	Prospects for mTOR targeting in adult T cell leukemia. <i>Leukemia and Lymphoma</i> , 2009 , 50, 525-6	1.9	1
91	Role of Schlafen 2 (SLFN2) in the generation of interferon alpha-induced growth inhibitory responses. <i>Journal of Biological Chemistry</i> , 2009 , 284, 25051-64	5.4	53
90	Interferon-dependent engagement of eukaryotic initiation factor 4B via S6 kinase (S6K)- and ribosomal protein S6K-mediated signals. <i>Molecular and Cellular Biology</i> , 2009 , 29, 2865-75	4.8	58
89	Regulation of leukemic cell differentiation and retinoid-induced gene expression by statins. <i>Molecular Cancer Therapeutics</i> , 2009 , 8, 615-25	6.1	11
88	Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinib. <i>Leukemia and Lymphoma</i> , 2009 , 50, 2017-29	1.9	37
87	Activation of protein kinase C{eta} by type I interferons. <i>Journal of Biological Chemistry</i> , 2009 , 284, 10305-14	5.4	16
86	Type I interferon (IFN)-dependent activation of Mnk1 and its role in the generation of growth inhibitory responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 12097-102	11.5	66
85	Growth suppressive cytokines and the AKT/mTOR pathway. <i>Cytokine</i> , 2009 , 48, 138-43	4	25

84	Biological responses to arsenic compounds. <i>Journal of Biological Chemistry</i> , 2009 , 284, 18583-7	5.4	120
83	Glutathione Depletion Enhances Arsenic Trioxide-Induced Apoptosis in Lymphoma Cells through Mitochondrial and Caspase-Independent Mechanisms.. <i>Blood</i> , 2009 , 114, 2708-2708	2.2	1
82	Statins in tumor suppression. <i>Cancer Letters</i> , 2008 , 260, 11-9	9.9	132
81	Inhibition of p38alpha MAPK disrupts the pathological loop of proinflammatory factor production in the myelodysplastic syndrome bone marrow microenvironment. <i>Leukemia and Lymphoma</i> , 2008 , 49, 1963-75	1.9	30
80	Akt and mRNA translation by interferons. <i>Cell Cycle</i> , 2008 , 7, 2112-6	4.7	24
79	Regulatory effects of mammalian target of rapamycin-mediated signals in the generation of arsenic trioxide responses. <i>Journal of Biological Chemistry</i> , 2008 , 283, 1992-2001	5.4	38
78	Suppression of programmed cell death 4 (PDCD4) protein expression by BCR-ABL-regulated engagement of the mTOR/p70 S6 kinase pathway. <i>Journal of Biological Chemistry</i> , 2008 , 283, 8601-10	5.4	61
77	Role of the Akt pathway in mRNA translation of interferon-stimulated genes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 4808-13	11.5	156
76	Regulation of arsenic trioxide-induced cellular responses by Mnk1 and Mnk2. <i>Journal of Biological Chemistry</i> , 2008 , 283, 12034-42	5.4	33
75	Statin-dependent suppression of the Akt/mammalian target of rapamycin signaling cascade and programmed cell death 4 up-regulation in renal cell carcinoma. <i>Clinical Cancer Research</i> , 2008 , 14, 4640-9 ^{12.9}	5.4	54
74	Suppression of interferon (IFN)-inducible genes and IFN-mediated functional responses in BCR-ABL-expressing cells. <i>Journal of Biological Chemistry</i> , 2008 , 283, 10793-803	5.4	19
73	Protein kinase C signalling in leukemia. <i>Leukemia and Lymphoma</i> , 2008 , 49, 1255-62	1.9	14
72	Dual regulatory roles of phosphatidylinositol 3-kinase in IFN signaling. <i>Journal of Immunology</i> , 2008 , 181, 7316-23	5.3	67
71	Exploiting the mammalian target of rapamycin pathway in hematologic malignancies. <i>Current Opinion in Hematology</i> , 2008 , 15, 88-94	3.3	26
70	Regulatory effects of mammalian target of rapamycin-activated pathways in type I and II interferon signaling. <i>Journal of Biological Chemistry</i> , 2007 , 282, 1757-68	5.4	91
69	Suppressive effects of statins on acute promyelocytic leukemia cells. <i>Cancer Research</i> , 2007 , 67, 4524-32 ^{10.1}	5.4	67
68	The protein kinase C (PKC) family of proteins in cytokine signaling in hematopoiesis. <i>Journal of Interferon and Cytokine Research</i> , 2007 , 27, 623-36	3.5	44
67	Role of the p38 mitogen-activated protein kinase pathway in the generation of arsenic trioxide-dependent cellular responses. <i>Cancer Research</i> , 2006 , 66, 6763-71	10.1	71

66	Activation of mammalian target of rapamycin and the p70 S6 kinase by arsenic trioxide in BCR-ABL-expressing cells. <i>Molecular Cancer Therapeutics</i> , 2006 , 5, 2815-23	6.1	23
65	Activation of the mitogen- and stress-activated kinase 1 by arsenic trioxide. <i>Journal of Biological Chemistry</i> , 2006 , 281, 22446-52	5.4	48
64	MTHFR polymorphisms and the development of acute leukemia: does it really matter?. <i>Leukemia and Lymphoma</i> , 2006 , 47, 2002-3	1.9	2
63	Interferon-inducible genes and aplastic anemia. <i>Blood</i> , 2006 , 107, 2-3	2.2	1
62	Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors. <i>Blood</i> , 2006 , 108, 4170-7	2.2	108
61	Targeting the mTOR Pathway Suppresses the Growth of Acute Myeloid Leukemia (AML) Progenitors and Enhances Arsenic Trioxide Induced Antileukemic Responses.. <i>Blood</i> , 2006 , 108, 1898-1898 ²	2.2	108
60	Vitamin D and acute promyelocytic leukemia. <i>Leukemia and Lymphoma</i> , 2006 , 47, 581	1.9	
59	The p38 mitogen-activated protein kinase pathway in interferon signal transduction. <i>Journal of Interferon and Cytokine Research</i> , 2005 , 25, 749-56	3.5	64
58	Interferons. <i>Cancer Treatment and Research</i> , 2005 , 126, 45-68	3.5	12
57	Genistein inhibits p38 map kinase activation, matrix metalloproteinase type 2, and cell invasion in human prostate epithelial cells. <i>Cancer Research</i> , 2005 , 65, 3470-8	10.1	176
56	Activation of the p70 S6 kinase by all-trans-retinoic acid in acute promyelocytic leukemia cells. <i>Blood</i> , 2005 , 105, 1669-77	2.2	44
55	Differential regulation of the p70 S6 kinase pathway by interferon alpha (IFNalpha) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells. <i>Blood</i> , 2005 , 106, 2436-43	2.2	56
54	Mechanisms of type-I- and type-II-interferon-mediated signalling. <i>Nature Reviews Immunology</i> , 2005 , 5, 375-86	36.5	2190
53	Role of protein kinase C-delta (PKC-delta) in the generation of the effects of IFN-alpha in chronic myelogenous leukemia cells. <i>Experimental Hematology</i> , 2005 , 33, 550-7	3.1	34
52	Activation of mitogen-activated protein kinase kinase (MKK) 3 and MKK6 by type I interferons. <i>Journal of Biological Chemistry</i> , 2005 , 280, 10001-10	5.4	29
51	Introduction: interferon signals: what is classical and what is nonclassical?. <i>Journal of Interferon and Cytokine Research</i> , 2005 , 25, 732	3.5	25
50	The PI3' kinase pathway in interferon signaling. <i>Journal of Interferon and Cytokine Research</i> , 2005 , 25, 780-7	3.5	62
49	A role for mixed lineage kinases in regulating transcription factor CCAAT/enhancer-binding protein-{beta}-dependent gene expression in response to interferon-{gamma}. <i>Journal of Biological Chemistry</i> , 2005 , 280, 24462-71	5.4	21

48	Role of the p38 mitogen-activated protein kinase pathway in cytokine-mediated hematopoietic suppression in myelodysplastic syndromes. <i>Cancer Research</i> , 2005 , 65, 9029-37	10.1	54
47	Role of p38alpha Map kinase in Type I interferon signaling. <i>Journal of Biological Chemistry</i> , 2004 , 279, 970-9	5.4	86
46	Differential regulation of membrane type 1-matrix metalloproteinase activity by ERK 1/2- and p38 MAPK-modulated tissue inhibitor of metalloproteinases 2 expression controls transforming growth factor-beta1-induced pericellular collagenolysis. <i>Journal of Biological Chemistry</i> , 2004 , 279, 39042-50	5.4	114
45	Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells. <i>Journal of Biological Chemistry</i> , 2004 , 279, 25345-52	5.4	57
44	Engagement of protein kinase C-theta in interferon signaling in T-cells. <i>Journal of Biological Chemistry</i> , 2004 , 279, 29911-20	5.4	46
43	Signalling pathways activated by all-trans-retinoic acid in acute promyelocytic leukemia cells. <i>Leukemia and Lymphoma</i> , 2004 , 45, 2175-85	1.9	23
42	Interferon-gamma engages the p70 S6 kinase to regulate phosphorylation of the 40S S6 ribosomal protein. <i>Experimental Cell Research</i> , 2004 , 295, 173-82	4.2	71
41	Mechanisms of type-I interferon signal transduction. <i>BMB Reports</i> , 2004 , 37, 635-41	5.5	31
40	Activation of the p70 S6 kinase and phosphorylation of the 4E-BP1 repressor of mRNA translation by type I interferons. <i>Journal of Biological Chemistry</i> , 2003 , 278, 27772-80	5.4	102
39	Interferons: mechanisms of action and clinical applications. <i>Current Opinion in Oncology</i> , 2003 , 15, 431-9	4.2	145
38	Map kinase signaling pathways and hematologic malignancies. <i>Blood</i> , 2003 , 101, 4667-79	2.2	361
37	Jak family of kinases in cancer. <i>Cancer and Metastasis Reviews</i> , 2003 , 22, 423-34	9.6	102
36	The p38 mitogen-activated protein kinase pathway and its role in interferon signaling 2003 , 98, 129-42		122
35	Role of Stat5 in type I interferon-signaling and transcriptional regulation. <i>Biochemical and Biophysical Research Communications</i> , 2003 , 308, 325-30	3.4	52
34	Activation of protein kinase C delta by IFN-gamma. <i>Journal of Immunology</i> , 2003 , 171, 267-73	5.3	111
33	Activation of protein kinase C delta by all-trans-retinoic acid. <i>Journal of Biological Chemistry</i> , 2003 , 278, 32544-51	5.4	94
32	Activation of the p38 mitogen-activated protein kinase mediates the suppressive effects of type I interferons and transforming growth factor-beta on normal hematopoiesis. <i>Journal of Biological Chemistry</i> , 2002 , 277, 7726-35	5.4	133
31	Signaling via the interferon-alpha receptor in chronic myelogenous leukemia cells. <i>Leukemia and Lymphoma</i> , 2002 , 43, 703-9	1.9	34

30	Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to arsenic trioxide. <i>Journal of Biological Chemistry</i> , 2002 , 277, 44988-95	5.4	96
29	Cutting edge: activation of the p38 mitogen-activated protein kinase signaling pathway mediates cytokine-induced hemopoietic suppression in aplastic anemia. <i>Journal of Immunology</i> , 2002 , 168, 5984-8	5.3	87
28	MEKK1 plays a critical role in activating the transcription factor C/EBP-beta-dependent gene expression in response to IFN-gamma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002 , 99, 7945-50	11.5	74
27	Protein kinase C-delta (PKC-delta) is activated by type I interferons and mediates phosphorylation of Stat1 on serine 727. <i>Journal of Biological Chemistry</i> , 2002 , 277, 14408-16	5.4	173
26	The CrkL adapter protein is required for type I interferon-dependent gene transcription and activation of the small G-protein Rap1. <i>Biochemical and Biophysical Research Communications</i> , 2002 , 291, 744-50	3.4	33
25	Engagement of the CrkL adaptor in interferon alpha signalling in BCR-ABL-expressing cells. <i>British Journal of Haematology</i> , 2001 , 112, 327-36	4.5	29
24	ERK1 and ERK2 activate CCAAT/enhancer-binding protein-beta-dependent gene transcription in response to interferon-gamma. <i>Journal of Biological Chemistry</i> , 2001 , 276, 287-97	5.4	124
23	The p38 MAPK pathway mediates the growth inhibitory effects of interferon-alpha in BCR-ABL-expressing cells. <i>Journal of Biological Chemistry</i> , 2001 , 276, 28570-7	5.4	117
22	Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to all-trans-retinoic acid. <i>Journal of Biological Chemistry</i> , 2001 , 276, 4012-9	5.4	136
21	IFN-gamma activates the C3G/Rap1 signaling pathway. <i>Journal of Immunology</i> , 2000 , 164, 1800-6	5.3	62
20	The Rac1/p38 mitogen-activated protein kinase pathway is required for interferon alpha-dependent transcriptional activation but not serine phosphorylation of Stat proteins. <i>Journal of Biological Chemistry</i> , 2000 , 275, 27634-40	5.4	160
19	Engagement of the CrkL adaptor in interleukin-5 signaling in eosinophils. <i>Journal of Biological Chemistry</i> , 2000 , 275, 33167-75	5.4	23
18	Interferon-dependent activation of the serine kinase PI 3'-kinase requires engagement of the IRS pathway but not the Stat pathway. <i>Biochemical and Biophysical Research Communications</i> , 2000 , 270, 158-62	3.4	62
17	The proximal tyrosines of the cytoplasmic domain of the beta chain of the type I interferon receptor are essential for signal transducer and activator of transcription (Stat) 2 activation. Evidence that two Stat2 sites are required to reach a threshold of interferon alpha-induced Stat2 tyrosine phosphorylation that allows normal formation of interferon-stimulated gene factor 3.	5.4	40
16	Activation of the p38 mitogen-activated protein kinase by type I interferons. <i>Journal of Biological Chemistry</i> , 1999 , 274, 30127-31	5.4	188
15	Engagement of Gab1 and Gab2 in erythropoietin signaling. <i>Journal of Biological Chemistry</i> , 1999 , 274, 24469-74	5.4	86
14	Activation of a CrkL-stat5 signaling complex by type I interferons. <i>Journal of Biological Chemistry</i> , 1999 , 274, 571-3	5.4	105
13	CrkL and CrkII participate in the generation of the growth inhibitory effects of interferons on primary hematopoietic progenitors. <i>Experimental Hematology</i> , 1999 , 27, 1315-21	3.1	50

12	Interferon alpha activates the tyrosine kinase Lyn in haemopoietic cells. <i>British Journal of Haematology</i> , 1998 , 101, 446-9	4.5	11
11	The type I interferon receptor mediates tyrosine phosphorylation of the CrkL adaptor protein. <i>Journal of Biological Chemistry</i> , 1997 , 272, 29991-4	5.4	78
10	The vav proto-oncogene product (p95vav) interacts with the Tyk-2 protein tyrosine kinase. <i>FEBS Letters</i> , 1997 , 403, 31-4	3.8	28
9	Differences in interferon alpha and beta signaling. Interferon beta selectively induces the interaction of the alpha and betaL subunits of the type I interferon receptor. <i>Journal of Biological Chemistry</i> , 1996 , 271, 23630-3	5.4	82
8	The type I interferon receptor mediates tyrosine phosphorylation of insulin receptor substrate 2. <i>Journal of Biological Chemistry</i> , 1996 , 271, 278-82	5.4	99
7	Association of the interferon-dependent tyrosine kinase Tyk-2 with the hematopoietic cell phosphatase. <i>Journal of Biological Chemistry</i> , 1995 , 270, 18179-82	5.4	95
6	Interferon-alpha engages the insulin receptor substrate-1 to associate with the phosphatidylinositol 3'-kinase. <i>Journal of Biological Chemistry</i> , 1995 , 270, 15938-41	5.4	160
5	Interaction of the transcriptional activator Stat-2 with the type I interferon receptor. <i>Journal of Biological Chemistry</i> , 1995 , 270, 24627-30	5.4	37
4	Interferons. <i>Current Opinion in Oncology</i> , 1995 , 7, 560-565	4.2	29
3	Expression of the IFN alpha receptor in hairy cell leukaemia. <i>British Journal of Haematology</i> , 1992 , 82, 541-6	4.5	14
2	Hairy cell leukaemia: the role of alpha interferon. <i>European Journal of Cancer & Clinical Oncology</i> , 1991 , 27 Suppl 4, S53-7		5
1	Relapse of Hodgkin's Disease After 14 Years of Complete Remission. <i>Leukemia and Lymphoma</i> , 1990 , 3, 223-6	1.9	4